Jan Paul de Boer

9.3k total citations · 2 hit papers
118 papers, 3.9k citations indexed

About

Jan Paul de Boer is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jan Paul de Boer has authored 118 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 40 papers in Otorhinolaryngology and 38 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jan Paul de Boer's work include Head and Neck Cancer Studies (40 papers), Lymphoma Diagnosis and Treatment (23 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Jan Paul de Boer is often cited by papers focused on Head and Neck Cancer Studies (40 papers), Lymphoma Diagnosis and Treatment (23 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Jan Paul de Boer collaborates with scholars based in Netherlands, United States and Germany. Jan Paul de Boer's co-authors include Daphne de Jong, Flora E. van Leeuwen, Berthe M.P. Aleman, Dorina Roem, Harry Bartelink, Marie L. De Bruin, Alexandra W. van den Belt‐Dusebout, Mars B. van ’t Veer, Marianne A. Kuenen and Augustinus A. M. Hart and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jan Paul de Boer

112 papers receiving 3.8k citations

Hit Papers

Late cardiotoxicity after treatment for Hodgkin lymphoma 2006 2026 2012 2019 2006 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Late cardiotoxicity after treatment for Hodgkin lymphoma
    2006 532 citations Berthe M.P. Aleman, Marie L. De Bruin et al. Blood profile →
  2. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
    2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Paul de Boer Netherlands 35 1.6k 1.1k 788 698 607 118 3.9k
Paolo Pedrazzoli Italy 38 1.9k 1.2× 332 0.3× 747 0.9× 723 1.0× 172 0.3× 288 5.5k
Patrick Paulus Austria 30 644 0.4× 893 0.8× 1.1k 1.3× 576 0.8× 91 0.1× 75 3.7k
Chih‐Cheng Chen Taiwan 27 708 0.4× 347 0.3× 378 0.5× 520 0.7× 195 0.3× 126 2.6k
Daniel Albo United States 33 1.8k 1.1× 254 0.2× 753 1.0× 1.5k 2.2× 186 0.3× 91 4.1k
Patrizia Morbini Italy 34 726 0.4× 215 0.2× 1.0k 1.3× 1.0k 1.5× 211 0.3× 155 3.8k
Kadri Altundağ Türkiye 30 2.5k 1.5× 339 0.3× 915 1.2× 325 0.5× 94 0.2× 251 3.9k
Dian Wang United States 30 1.2k 0.7× 142 0.1× 1.5k 1.9× 762 1.1× 504 0.8× 156 3.6k
Mairéad G. McNamara United Kingdom 35 4.6k 2.8× 429 0.4× 1.8k 2.3× 2.3k 3.3× 148 0.2× 203 6.8k
Satoshi Yamamoto Japan 33 701 0.4× 273 0.3× 1.0k 1.3× 1.6k 2.2× 111 0.2× 252 4.0k
Yuhong Li China 38 2.3k 1.4× 514 0.5× 1.6k 2.0× 1.2k 1.8× 430 0.7× 212 5.6k

Countries citing papers authored by Jan Paul de Boer

Since Specialization
Citations

This map shows the geographic impact of Jan Paul de Boer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Paul de Boer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Paul de Boer more than expected).

Fields of papers citing papers by Jan Paul de Boer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Paul de Boer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Paul de Boer. The network helps show where Jan Paul de Boer may publish in the future.

Co-authorship network of co-authors of Jan Paul de Boer

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Paul de Boer. A scholar is included among the top collaborators of Jan Paul de Boer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Paul de Boer. Jan Paul de Boer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smit, Laura A., Jan Paul de Boer, Arash Navran, et al.. (2025). [18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial. European Journal of Nuclear Medicine and Molecular Imaging. 53(4). 2217–2233.
2.
Boer, Esther de, Gerard van Mierlo, Liudmila L. Kodach, et al.. (2025). Distinct sites of complement activation and regulation in the tumor microenvironment. Immunobiology. 230(4). 152952–152952.
3.
Boer, Jan Paul de, Lisette van der Molen, Abrahim Al‐Mamgani, et al.. (2024). The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin‐based chemoradiotherapy in patients with head and neck squamous cell carcinoma. Head & Neck. 47(1). 189–200. 1 indexed citations
4.
Mols, Floortje, Dounya Schoormans, Romana T. Netea‐Maier, et al.. (2023). Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study. Thyroid Research. 16(1). 23–23. 4 indexed citations
5.
Donswijk, Maarten L., et al.. (2023). Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer. European Radiology. 33(5). 3377–3385. 3 indexed citations
6.
Gini, Andrea, Manon C.W. Spaander, Leon M.G. Moons, et al.. (2022). Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy. Cancer Epidemiology Biomarkers & Prevention. 31(12). 2157–2168. 3 indexed citations
7.
Boer, Jan Paul de, Frederieke van Duijnhoven, Jacqueline E. van der Wal, et al.. (2022). The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice. BMC Cancer. 22(1). 1018–1018. 8 indexed citations
8.
Boer, Jan Paul de, Menno R. Vriens, Rachel S. van Leeuwaarde, et al.. (2021). Retrospective Analyses of 18 FDG-PET/CT Thyroid Incidentaloma in Adults: Incidence, Treatment, and Outcome in a Tertiary Cancer Referral Center. Thyroid. 31(11). 1715–1722. 5 indexed citations
9.
Postma, Emily L., Jan Paul de Boer, Annelies M. E. Bos, et al.. (2020). The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis. Thyroid. 31(4). 658–668. 22 indexed citations
10.
Boer, Mintsje de, Michael Hauptmann, Nathalie J. Hijmering, et al.. (2020). Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast. Blood. 136(11). 1368–1372. 25 indexed citations
11.
Vries, G. Tjitske Los-de, Mintsje de Boer, Erik van Dijk, et al.. (2020). Chromosome 20 loss is characteristic of breast implant–associated anaplastic large cell lymphoma. Blood. 136(25). 2927–2932. 35 indexed citations
12.
Armand, Philippe, Andreas Engert, Anas Younes, et al.. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology. 36(14). 1428–1439. 455 indexed citations breakdown →
13.
Elbers, Joris B.W., Abrahim Al‐Mamgani, Michiel W. M. van den Brekel, et al.. (2018). Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Otolaryngology. 160(6). 1023–1033. 22 indexed citations
14.
Eggermond, Anna M. van, Michael Schaapveld, Cécile P.M. Janus, et al.. (2017). Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. British Journal of Cancer. 117(3). 306–314. 18 indexed citations
15.
Jasperse, Bas, Jan‐Jakob Sonke, Wilma D. Heemsbergen, et al.. (2017). A predictive model for residual disease after (chemo) radiotherapy in oropharyngeal carcinoma: Combined radiological and clinical evaluation of tumor response. Clinical and Translational Radiation Oncology. 6. 1–6. 5 indexed citations
16.
Houtenbos, Ilse, Jan Paul de Boer, Aart Beeker, et al.. (2016). Diffuse large B-cell lymphoma with MYC gene rearrangements. European Journal of Cancer. 55. 140–146. 15 indexed citations
17.
18.
Schaapveld, Michael, et al.. (2015). Cause-specific excess mortality in patients treated for cancer of the oral cavity and oropharynx: A population-based study. Oral Oncology. 52. 37–44. 13 indexed citations
19.
Zuur, Charlotte L., Marta López‐Yurda, S. van der Baan, et al.. (2014). Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: A long-term follow-up study. Journal of Otolaryngology - Head and Neck Surgery. 43(1). 30–30. 16 indexed citations
20.
Wildeman, Maarten A., Zlata Novalić, Sandra A.W.M. Verkuijlen, et al.. (2012). Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors. Clinical Cancer Research. 18(18). 5061–5070. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Pedrazzoli Breakdown of academic impact, for papers by Patrick Paulus Breakdown of academic impact, for papers by Chih‐Cheng Chen Breakdown of academic impact, for papers by Daniel Albo Breakdown of academic impact, for papers by Patrizia Morbini Breakdown of academic impact, for papers by Kadri Altundağ Breakdown of academic impact, for papers by Dian Wang Breakdown of academic impact, for papers by Mairéad G. McNamara Breakdown of academic impact, for papers by Satoshi Yamamoto Breakdown of academic impact, for papers by Yuhong Li
Rankless by CCL
2026